改良FOLFOX6化疗方案联合奥曲肽对于改善晚期肝癌患者临床症状及生活质量的效果分析

Effect of Modified FOLFOX6 Chemotherapy Regimen Combined with Octreotide in Improving Clinical Symptoms and Quality of Life of Patients with Advanced Hepatocellular Carcinoma

目的探讨改良FOLFOX6化疗方案联合奥曲肽对于改善晚期肝癌患者临床症状及生活质量的效果。方法选择105例晚期原发性肝癌患者,按照随机数字法将患者分实验组与对照组。对照组患者采用改良FOLFOX6化疗方案治疗,实验组则在对照组的基础上加用奥曲肽注射液进行治疗。比较2组患者的临床疗效、生活质量提高率、临床症状改善率及毒副作用。结果实验组肝癌患者治疗的总有效率为58.49%,显著高于对照组30.77%,2组差异具有统计学意义(P<0.05)。实验组患者的生活质量提高率为52.83%,明显优于对照组30.77%,2组差异具有统计学意义(P<0.05)。2组患者经相应的治疗后临床症状均有不同程度上的改善,实验组在腹腔积液、腹胀、疲乏及肝痛症状改善有效率上明显优于对照组,比较差异均具有统计学意义(P<0.05);而食减改善有效率比较差异无统计学意义。实验组白细胞和血小板减少程度均显著优于对照组,比较差异均具有统计学意义(P<0.05)。结论改良FOLFOX6化疗方案联合奥曲肽对于晚期肝癌患者具有较高的临床疗效,能较好地改善患者的临床症状,提高生活质量,且安全性高,不良反应较少。

Objective To explore the effect of modified FOLFOX6 chemotherapy regimen combined with octreotide in improving clinical symptoms and quality of life of patients with advanced hepatocellular carcinoma. Methods 105 patients with advanced hepatocellular carcinoma were randomly divided into the experimental group and the control group, the control group were treated with modified treatment, the experimental group on the basis of the control group received octreotide injection, clinical efficacy, quality of life improvement rates, improvement rates of clinical symptoms and side effects of the 2 groups were compared. Results The total effective rate of the experimental group was 58.49% ,which was significantly higher than 30.77% of the con- trol group, the difference was statistically significant （ P 〈 0.05 ）. The quality of life of the experimental group was increased by 52.83 % , which was significantly higher than 30.77 % of the control group, the difference was statistically significant （ P 〈 0.05 ）. Clinical symptoms of the 2 groups were improved after corresponding treatment. Ascites, bloating, fatigue,liver pain symptoms effi- ciency improvement rate of the experimental group was superior to the control group ,the difference was statistically significant（ P 〈 O. 05 ）, while efficiency improvement rate of food minus of the 2 groups bad no statistically significant difference. White cells and platelets reduction degree of the experimental group were significantly better than the control group, the difference was statisti- cally significant （ P 〈 0.05 ）. Conclusion Modified FOLFOX6 chemotherapy regimen with octreotide for advanced hepatoeellular carcinoma have high clinical efficacy and safety,it can improve clinical symptoms and quality of life with less toxicity.